Lexington, KY and San Antonio, TX (January 16, 2013) – San Antonio, Texas-based Biomedical Development Corp. is expanding its operations to Lexington after securing two grants from the Kentucky SBIR-STTR Matching Funds Program. Aligned with the innovative grant program and the University of Kentucky, 28-year-old BDC aims to extend its successful record investing in healthcare technologies.
BDC’s Kentucky operations will focus on two initiatives, a mouth rinse that fights oral inflammation and a patient management software designed to better understand and treat bipolar disorder.
Company founder and CEO Phyllis Siegel explained the strategy behind the expansion as “…an opportunity to bring new products to the market.” She said, “The state of Kentucky has provided some very forward-thinking financial and programming incentives for Biomedical to move here because of the commercial potential of our products and the expertise of the company. We are meeting members of an open and progressive startup community and look forward to being part of the regional ecosystem.”
In an upcoming clinical trial, a new mouth rinse will be tested in collaboration with the Center for Oral Health Research at the University of Kentucky. The mouth rinse is a unique product because it fights oral inflammation and may lower high cholesterol. It has been previously tested in three human clinical trials. The fourth trial will begin in January 2013. This research is funded by the National Heart, Lung, and Blood Institute.
KIOS Health™, the patient management software, provides real time support for bipolar patients, doctors, and caregivers. The product will provide expert advice based on the individualized trajectory of a patient’s disease course. This will enable patients to have greater control over their health. An Internet-based application is being developed and will be tested in early 2013. This research is funded by the National Institute of Mental Health.